Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Analytikerkommentar

OptiCept Q2’24 earnings preview: Strong revenue growth expected

Av Lucas MattssonAnalytiker
OptiCept Technologies

Opti Cept Q2'24 Preview

OptiCept will release its Q2 results on Thursday. We expect strong revenue growth mainly due to higher deliveries within FoodTech. Profitability is expected to remain negative due to the still low absolute revenue level. In the upcoming Q2 report, we are looking for any comments on the delivery progress of the large-scale order from FPS, as well as information regarding ongoing evaluations in both business areas.

High revenue growth expected

We anticipate OptiCept's Q2 revenue to land at 9.4 MSEK, which represents high growth of 326% year-on-year, albeit from low absolute levels. The revenue is expected to be driven by the FoodTech business area, which we estimate will constitute some 70% of total Q2 revenue. The business area’s revenue growth likely stems mainly from OliveCept installations in Spain. In the PlantTech segment, we expect growth to be driven by increased revenue from the commercial deal with APH in cut flowers, as well as increased volumes from CMPC and Aperam in cuttings. We expect the order book to remain at high levels, some 40-50 MSEK, due to a significant portion of the total order book is tied to not yet delivered OliveCept systems and orders from FPS.

Profitability still in the red

We expect the company to reduce operating costs, excluding COGS, by approximately 20% year-over-year as a result of cost-cutting measures. However, due to the still low absolute level of revenues, which do not yet cover fixed costs, we expect OptiCept's Q2 profitability to remain negative in all lines, with our EBITDA and EBIT estimates at -4.7 MSEK and -10.1 MSEK, respectively. In terms of cash flow, we expect the negative operating result and the increased working capital tied up in the production and delivery of the large order to FPS to put pressure on cash flow. However, we expect that the loan of 18.7 MSEK received in June will partially offset the negative operating cash flow.

Order book conversion and technology evaluations in focus

Our current full-year estimates for 2024 and 2025 are around 47 MSEK and 89 MSEK, respectively. In order for OptiCept to achieve these estimates, the company must ensure that deliveries to FPS remain on schedule, increase order intake and successfully convert more of the order backlog into deliveries. As such, we will be watching for any updates on the delivery progress of the large FPS order, as well as the ongoing evaluations with, e.g., Dole and Chrysal, which we believe will be critical to the company's business growth prospects. We also look forward to comments on the existing commercial contracts for OptiCept within PlantTech.

OptiCept Technologies

6,03SEK2024-08-26 18:00

OptiCept Technologies förser livsmedels-och växtindustrin med teknologiska lösningar som används för att öka hållbarheten för diverse råvaror. Bolaget arbetar med biologiska processer som ger en ökad extraktion ur råvaran, minskat avfall samt bibehållen smak, doft, färg, näringsinnehåll. Bolaget har en patenterad teknologi inom PEF (pulsed electric field) och VI (Vacuum Infusion). Bolaget säljer sina produkter på en global nivå och har sitt huvudkontor i Lund.

Läs mera
Forum uppdateringar
Har missat senaste analysen om OptiCept? Läs den här: Inderes OptiCept Q3'24: Secures crucial funding for growth - Inderes The capital raise...
2024-11-25 07:57
by Jesper Hagman
1
Jesper intervjuade analytiker Lucas om företaget och dess Q3. Inderes OptiCept Q3´24: Säkerställer viktig finansiering för tillväxt - Inderes...
2024-10-23 21:53
by börsen84
1
OptiCept har tecknat ett hyresavtal med det centralamerikanska företaget Mexifrutas om att hyra OptiCepts PEF-system för att effektivisera extraktione...
2024-10-16 22:43
by börsen84
1
OptiCept har meddelat att deras kund La Salud har fått ekonomiskt stöd från EU, vilket var en viktig förutsättning för att gå vidare med den...
2024-09-18 14:01
by börsen84
0
OptiCept has announced that it has entered into a Memorandum of Understanding (MoU) with Saab, a key player within the defense industry. The...
2024-09-09 07:56
by Jesper Hagman
1
Under första halvåret har OptiCept gjort betydande framsteg mot att nå en bredare kommersialisering. OptiCept har bland annat säkrat sin första...
2024-08-30 07:22
by Jesper Hagman
2
Analytikerkommentar inför Q2 rapporten från OptiCept: Inderes OptiCept Q2’24 earnings preview: Strong revenue growth expected - Inderes OptiCept...
2024-08-27 08:03
by Jesper Hagman
3
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Our team
  • Careers
  • Inderes som en investering
  • Tjänster för börsbolag
Our platform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.